Advertisement
Australia markets open in 6 hours 23 minutes
  • ALL ORDS

    8,065.50
    +113.20 (+1.42%)
     
  • AUD/USD

    0.6601
    -0.0024 (-0.37%)
     
  • ASX 200

    7,793.30
    +110.90 (+1.44%)
     
  • OIL

    79.00
    +0.52 (+0.66%)
     
  • GOLD

    2,323.80
    -7.40 (-0.32%)
     
  • Bitcoin AUD

    96,071.43
    +498.41 (+0.52%)
     
  • CMC Crypto 200

    1,316.57
    -48.55 (-3.56%)
     

T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2020 after market close on Wednesday, November 4, 2020. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 877-407-9208 (U.S.) or 201-493-6784 (International) five to ten minutes prior to the start time.

About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763

Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406